NY State Senate Bill 2025-S1029

Senate Bill S1029

2025-2026 Legislative Session

Directs the commissioner of health to conduct a study to identify, analyze, report, and medically combat new or previously unseen opiate/opioid compounds found in overdose patients in New York state

download bill text pdf

Current Bill Status - In Senate Committee Mental Health Committee

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Delivered to Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
Jan 08, 2025	referred to mental health

co-Sponsors

2025-S1029 (ACTIVE) - Details

Current Committee:: Senate Mental Health
Law Section:: Health, Commissioner of
Versions Introduced in 2023-2024 Legislative Session:: S9890

2025-S1029 (ACTIVE) - Summary

Directs the commissioner of health to conduct a study to identify, analyze, report, and medically combat new or previously unseen opiate/opioid compounds found in overdose patients in New York state for the purpose of establishing more efficient overdose medical treatment protocols.

2025-S1029 (ACTIVE) - Sponsor Memo

                                 
BILL NUMBER: S1029

SPONSOR: ROLISON
 
TITLE OF BILL:

An act directing the commissioner of health to conduct a study to iden-
tify, analyze, report, and medically combat new or previously unseen
opiate/opioid compounds found in overdose patients in New York state for
the purpose of establishing more efficient overdose medical treatment
protocols

 
PURPOSE OR GENERAL IDEA OF BILL:

Directs the commissioner of health to conduct a study to identify,
analyze, report, and medically combat new or previously unseen opiate/
opioid compounds found in overdose patients in New York state

 
SUMMARY OF PROVISIONS:

Section 1 - This Act shall be known and may be cited as the "identify
dangerous drugs act (IDDA)"

Section 2 - The opioid settlement fund advisory board shall direct the
commissioner of health to conduct a study of 250 random urine samples
collected anonymously throughout the state of New York. Provides for who
the samples shall be collected and from whom the samples will be
collected.

Section 3 - The samples collected in this study shall be only used for
the purposes of this study

Section 4 - All samples collected, obtained, stored, and transported
should follow department of health protocols. Such samples shall be sent
to a designated laboratory with access to advanced chromatographic tech-
niques, specifically liquid chromatography-tandem mass spectrometry and
gas chromatography-mass spectrometry.

Section 5 - The study findings, data, results, treatment recommendations
and suggested emergency room protocols shall be compiled into a report
published by the commissioner of health.

Section 6 - Within one year of the effective date the commissioner of
health shall submit the report to the governor, the temporary p resident
of the senate, the minority leader of the senate, the speaker of the
assembly, the minority leader of the assembly, and the chairs and rank-
ing members of the senate and assembly committees on health. As well as
post such report on the department of health's website.

Section 7 - The commissioner of health shall be authorized to promulgate
rules and regulations to implement the provisions of this act.

Section 8 - This act shall take effect immediately and shall expire and
be deemed repealed thirty days after the delivery of,the report.

 
JUSTIFICATION:

Hundreds of new deadly synthetic drugs have been introduced onto the
streets of New York since 2009, yet the drug testing utilized in hospi-
tals across the state is not capable of identifying the NPS (Novel
Psychoactive Substances). Patients cannot be diagnosed and properly
treated without knowing which drugs are in their system. The Identify
Dangerous Drugs Act (IDDA) will commission a study about overdose
patients receiving treatment in our hospitals. So that we can better
understand and help solve this issue that plagues New York.

Since 2009, several new synthetic opioids including fentanyl and nitaz-
enes have been introduced across New York State and the rest of the
country. These deadly substances often lead to terrible consequences
including thousands of deaths, addiction, and the destruction of fami-
lies. Their continued use often leads to repeated theft and/or violence
by people who suffer from addiction. Unless the new and commonly used
cpiate/opioid compounds, used in combination with other illicit
substances, are identified and studied, the patients cannot be properly
treated or given the proper antidotes to save their lives.

Emergency room or hospital-based toxicology labs do not have the neces-
sary equipment, trained personnel or time to identify these new synthet-
ic drugs and properly develop treatment protocols. Most hospitals only
have the equipment designed to detect basic street drugs and cannot
identify specific opiate analogs that cannot be combated by universal
opiate-reversal drugs such as Narcan.

Accordingly, comprehensive drug screening is expensive and generally not
covered by insurance. As a result, many overdose patients do not receive
medical treatment effectively targeting and combating their deadly symp-
toms related to the use of new or uncommon opiate/opioid analogs, addi-
tives or combinations of illicit drugs.

 
PRIOR LEGISLATIVE HISTORY:

2024 S9890: Referred to Rules

 
FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS:

To be determined

 
EFFECTIVE DATE:
Immediately

2025-S1029 (ACTIVE) - Bill Text download pdf

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   1029
 
                        2025-2026 Regular Sessions
 
                             I N  S E N A T E
 
                                (PREFILED)
 
                              January 8, 2025
                                ___________
 
 Introduced  by Sens. ROLISON, OBERACKER -- read twice and ordered print-
   ed, and when printed to be committed to the Committee on Mental Health
 
 AN ACT directing the commissioner of health to conduct a study to  iden-
   tify,  analyze,  report, and medically combat new or previously unseen
   opiate/opioid compounds found in overdose patients in New  York  state
   for the purpose of establishing more efficient overdose medical treat-
   ment protocols
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. This act shall be known and may be cited as  the  "identify
 dangerous drugs act (IDDA)".
   §  2.  The opioid settlement fund advisory board, established pursuant
 to section 25.18 of the mental hygiene law, shall direct the commission-
 er of health to conduct a study of 250 random  urine  samples  collected
 anonymously  throughout  the  state of New York. Such samples shall: (i)
 represent each county in the state; (ii) be provided in accordance  with
 HIPAA  laws  and  regulations; and (iii) be identified by emergency room
 hospital physicians as having been generated from patients who,  at  the
 time  of  collection, were experiencing moderate to severe medical symp-
 toms diagnosed as being directly related to an overdose associated  from
 the use of an illicit unidentified opioid/opiate substance and/or combi-
 nation of substances. Such urine samples shall:
   (a)  only  be  collected  from patients diagnosed by an emergency room
 physician as experiencing moderate  or  severe  overdose  symptoms  most
 likely related to opiate/opioid patient use;
   (b)  be collected by designated trained medical staff, including nurs-
 es, physicians, and physician assistants;
   (c) be collected in tandem with the written and verbal consent of  the
 patient  and follow all designated HIPAA laws and regulations, including
 but not limited to identifying samples only by number on a form supplied

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.

                                                            LBD01984-01-5
 S. 1029                             2
 
 to the hospital by the department of health. Such written consent  shall
 be  knowing  and  willful. The patient shall be verbally read conditions
 and forms by medical staff identified above and shall  sign  a  document
 supplied  by  the department of health. Patients shall verbalize consent
 to the medical staff collecting the sample,  as  identified  above,  and
 shall  be  assessed  by  such staff as having full mental capacity as to
 consent to a legal document;
   (d) be collected from a patient identified by the  treating  physician
 as  experiencing current moderate to severe opiate/opioid overdose symp-
 toms which may not have responded to emergency Narcan administration  or
 the  patient  may  be  experiencing  unusual or severe symptoms that the
 physician believes is related to opiate/opioid use, possibly in combina-
 tion with other drugs. The  treating  physician  must,  in  good  faith,
 believe  the  patient  is  experiencing moderate to severe opiate/opioid
 related symptoms at the time the sample is collected and that such symp-
 toms are from the use of illicit or non-prescribed medication  or  unin-
 tended use of prescribed medication in combination with an illicit drug.
   §  3.  The samples collected pursuant to section two of this act shall
 be obtained only for the purpose of the study commissioned  pursuant  to
 section  two  of  this act and shall not be accessed or reported for any
 other purpose including, but not limited to: use by law  enforcement  or
 the  office  of children and family services; consideration of probation
 or parole; or inclusion in the medical history of the patient. The study
 shall be conducted in good faith by all participating hospital staff and
 for the sole purpose of obtaining knowledge and information  related  to
 illicit opiate/opioid substance use.
   §  4.  All  samples  collected,  obtained,  stored, and transported by
 physicians and emergency room staff should follow protocols  established
 by  the  department  of health. Such samples shall be sent to one desig-
 nated laboratory with access  to  advanced  chromatographic  techniques,
 specifically  liquid  chromatography-tandem mass spectrometry (LC-MS-MS)
 and gas chromatography-mass spectrometry (GC-MS) to identify and measure
 a broad range of compounds, including new  or  unusual  opiate  analogs,
 xylazine or unidentified opiate/opioid compounds, combinations of illic-
 it substances, and prescription medications.
   §  5. The study findings, data, results, treatment recommendations and
 suggested emergency room protocols  shall  be  compiled  into  a  report
 published  by the commissioner of health which shall include recommended
 statewide treatment protocols and procedures. Such protocols and  proce-
 dures  shall  take into consideration that the use of Narcan on patients
 with opiate/opioid overdose symptoms may not be sufficient  for  combat-
 ting  a  medical  overdose  emergency in a patient experiencing symptoms
 from  new  or  unusual  opiate   analogs,   xylazine   or   unidentified
 opiate/opioid   compounds,   commonly   used   combinations  of  illicit
 substances, or the unintended use of prescribed medication as  found  in
 the samples.
   §  6. Within one year from the effective date of this act, the commis-
 sioner of health shall submit the report required  pursuant  to  section
 five of this act to the governor, the temporary president of the senate,
 the  minority  leader  of  the  senate, the speaker of the assembly, the
 minority leader of the assembly, and the chairs and ranking  members  of
 the  senate and assembly committees on health and shall post such report
 on the department of  health's  website.  All  hospitals  and  addiction
 treatment  facilities  shall be granted access to the report in a timely
 manner.
 S. 1029                             3
 
   § 7. The commissioner of health  shall  be  authorized  to  promulgate
 rules and regulations to implement the provisions of this act.
   § 8. This act shall take effect immediately and shall expire and shall
 be  deemed  repealed thirty days after the delivery of the report to the
 governor and the legislature as provided for in section six of this act;
 provided that the commissioner of health shall  notify  the  legislative
 bill  drafting  commission  upon  the  occurrence of the delivery of the
 report provided for in section six of this act in order that the commis-
 sion may maintain an accurate and timely  effective  data  base  of  the
 official  text  of  the  laws of the state of New York in furtherance of
 effectuating the provisions of section 44 of  the  legislative  law  and
 section 70-b of the public officers law.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Senate Bill S1029

Share this bill

Sponsored By

Rob Rolison